OBJECTIVES: To compare the clinical (safety, effectiveness) and humanistic (QoL and other PROs) outcomes associated with mepolizumab and benralizumab in the management of severe asthma in real-world settings

METHODS: We searched PubMed for relevant records on 9th November 2022, using appropriate search strategies. Publication details, demographics, intervention, comparator, effectiveness, safety and humanistic outcomes were extracted from eligible records.

RESULTS: Of 920 records screened, 7 studies (1 prospective and 6 retrospective observational studies) with a total of 867 unique patients with different forms of severe asthma (females: 489, males: 378) were included. Mean age of participants ranged from 46±13.9 years to 57.2±12.1 years. Dosing of mepolizumab and benralizumab was as per USFDA-recommended dosage in 3 and 2 studies respectively. Efficacy, safety, and PROs were reported in 7, 3, and 2 of the included studies, but there was a lack of uniformity in the metrics used to assess effectiveness outcomes in included studies. Both mepolizumab and benralizumab were associated with reduction in asthma exacerbations, improvements in Forced Expiratory Volume in 1 Second (FEV1), Forced Vital Capacity (FVC), and FEV1/FVC ratio, and improvements in quality of life (as evidenced by ACQ and AQLQ scores); the differences between the outcomes of the two drugs was not statistically significant. No new safety signals were detected.

CONCLUSIONS: Both mepolizumab and benralizumab are safe and effective in severe asthma patients treated in real-world settings. There were minimal differences in the effectiveness, safety and humanistic outcomes of mepolizumab and benralizumab in severe asthma.